|
Market Closed -
Toronto S.E.
16:00:00 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 2.670 CAD | +1.14% |
|
+3.49% | +103.82% |
Company Valuation: Cardiol Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 142 | 43.96 | 71.77 | 151 | 130.4 | 311.9 | - | - |
| Change | - | -69.05% | 63.28% | 110.34% | -13.65% | 139.27% | - | - |
| Enterprise Value (EV) 1 | 142 | 43.96 | 36.84 | 120.4 | 108.9 | 296.9 | 301.7 | 311.9 |
| Change | - | -69.05% | -16.19% | 226.78% | -9.5% | 172.53% | 1.6% | 3.4% |
| P/E | -3.19x | -1.41x | -2.5x | -3.63x | -3.36x | -8.5x | -9.42x | -42x |
| PBR | - | - | 2.55x | 6.18x | 6.41x | 15.2x | 27.8x | - |
| PEG | - | 0x | 0.2x | -0.2x | 0.1x | 0.4x | 0.97x | 0.5x |
| Capitalization / Revenue | 1,803x | - | - | - | - | - | 317x | 5.91x |
| EV / Revenue | 1,803x | - | - | - | - | - | 307x | 5.91x |
| EV / EBITDA | -4.74x | -1.07x | -1.25x | -3x | -3.18x | -11.5x | -19x | -15.1x |
| EV / EBIT | -3.67x | -1.06x | -1.24x | -2.99x | -3.17x | -8.1x | -8.68x | -49.6x |
| EV / FCF | -6.03x | - | -1.46x | -4.8x | -4.56x | -8.69x | -11x | -4.82x |
| FCF Yield | -16.6% | - | -68.5% | -20.8% | -21.9% | -11.5% | -9.08% | -20.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.73 | -0.49 | -0.44 | -0.51 | -0.39 | -0.314 | -0.2834 | -0.0635 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.0788 | - | - | - | - | - | 0.9842 | 52.75 |
| EBITDA 1 | -29.95 | -41.12 | -29.54 | -40.11 | -34.21 | -25.72 | -15.88 | -20.62 |
| EBIT 1 | -38.66 | -41.34 | -29.79 | -40.28 | -34.32 | -36.66 | -34.76 | -6.288 |
| Net income 1 | -31.64 | -30.93 | -28.13 | -36.68 | -33.82 | -36.31 | -36.46 | -15.29 |
| Net Debt 1 | - | - | -34.93 | -30.58 | -21.42 | -15.01 | -10.26 | - |
| Reference price 2 | 2.330 | 0.690 | 1.100 | 1.850 | 1.310 | 2.670 | 2.670 | 2.670 |
| Nbr of stocks (in thousands) | 60,954 | 63,703 | 65,247 | 81,603 | 99,514 | 116,823 | - | - |
| Announcement Date | 3/23/22 | 3/28/23 | 4/1/24 | 3/31/25 | 3/31/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.5x | - | -11.54x | - | 222M | |
| 32.89x | 5.91x | 17.69x | 0.99% | 47.86B | |
| 34.78x | 3.35x | 14.44x | -.--% | 44.46B | |
| 48.22x | 5.6x | 30.63x | -.--% | 41.85B | |
| -19.82x | 211.04x | -21.38x | -.--% | 41.34B | |
| 27.01x | 7.79x | 20.05x | 0.42% | 30.04B | |
| 35.84x | 5.89x | 26.75x | -.--% | 17.59B | |
| 26.32x | 2.25x | 9.76x | 1.02% | 15.69B | |
| -55.43x | 9.1x | 222.2x | -.--% | 13.93B | |
| Average | 13.48x | 31.36x | 34.29x | 0.3% | 28.11B | |
| Weighted average by Cap. | 21.35x | 39.13x | 24.53x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CRDL Stock
- Valuation Cardiol Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
